<DOC>
	<DOC>NCT02267343</DOC>
	<brief_summary>The purpose of study is to evaluate the efficacy and safety of ONO-4538 in patients with unresectable advanced or recurrent gastric cancer (including esophagogastric junction cancer) refractory to or intolerant of standard therapy.</brief_summary>
	<brief_title>Study of ONO-4538 in Unresectable Advanced or Recurrent Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Men &amp; women â‰¥20 years of age Unresectable advanced or recurrent gastric cancer (including esophagogastric junction cancer) Histologically confirmed adenocarcinoma Refractory to or intolerant of standard therapy ECOG Performance Status score 0 or 1 A life expectancy of at least 3 months Current or past history of severe hypersensitivity to any other antibody products Patients with multiple primary cancers Patients with any metastasis in the brain or meninx that is symptomatic or requires treatment Patients with active, known or suspected autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>